CLINICAL TRIALS PROFILE FOR PROVAYBLUE
✉ Email this page to a colleague
All Clinical Trials for PROVAYBLUE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03395223 ↗ | MEthylene Blue In Patients With Acquired Methemoglobinemia | Completed | Provepharm SAS | Phase 4 | 2018-07-06 | This is an open label, uncontrolled, Phase 4 study including 10 patients who present in hospital/urgent care setting with acquired methemoglobinemia. The population may include pediatric and adult patients (males and females of all ages are included). The study will run in both the EU and the US. The aim of the study is to confirm safety and efficacy of ProvayBlueTM for the treatment of acquired methemoglobinemia and has been requested by the US-FDA as a Post-Marketing requirements. |
| NCT04089072 ↗ | Methylene Blue as a Third-line Vasopressor in Septic Shock | Recruiting | Provepharm Life Solutions | Phase 2 | 2019-12-01 | A randomized, prospective study comparing ProvayBlue® to standard care with multiple sympathomimetic vasopressors. |
| NCT04089072 ↗ | Methylene Blue as a Third-line Vasopressor in Septic Shock | Recruiting | Carilion Clinic | Phase 2 | 2019-12-01 | A randomized, prospective study comparing ProvayBlue® to standard care with multiple sympathomimetic vasopressors. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PROVAYBLUE
Condition Name
Clinical Trial Locations for PROVAYBLUE
Trials by Country
Clinical Trial Progress for PROVAYBLUE
Clinical Trial Phase
Clinical Trial Sponsors for PROVAYBLUE
Sponsor Name
